Pharmacokinetics and liver targeting of lyophilized albendazole nanoliposomes in rats

Hui-jing GAO,Bei CHEN,Hai-bo ZHANG,Chun-yan CHEN,Xiao-yan CHEN,Jian-hua WANG,Jun ZHAO
DOI: https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2017.08.08
2017-01-01
Abstract:OBJECTIVE To research the phamacokinetics and liver targeting of lyophilized albendazole nanoliposomes (NL-ABZ) in rats.METHODS After rats were orally administrated abendazole tablets (T-ABZ),albendazole liposomes (L-ABZ)and lyophilized albendazole nanoliposomes (NL-ABZ),blood and liver samples were collected at different time points.The samples were pretreated and analyzed by high performance liquid chromatography (HPLC) system,and then the differences of phamacokinetics parameters and liver targeting were analyzed.RESULTS Pharmacokinetics of lyophilized NL-ABZ:Cmax was (7.05± 0.70) μg·mL-1,tmx was (6.15 ± 0.66) h,AUC0-∞ was (150.9 ± 12.1) μg·mL-1 ·h.Compared with T-ABZ and L-ABZ,relative bioavailabilities of lyophilized NL-ABZ were 236.04% and 178.45 %,respectively,and liver had obviously increased distribution of lyophilized albendazole nanoliposomes.CONCLUSION The lyophilized NL-ABZ can improve bioavailability and liver targeting significantly.
What problem does this paper attempt to address?